Immutep Limited (IMM.XA)
| Previous close | 0.4350 |
| Open | 0.4200 |
| Bid | 0.4200 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.4150 - 0.4250 |
| 52-week range | 0.2250 - 0.4500 |
| Volume | |
| Avg. volume | 1,387,489 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0350 |
| Earnings date | 28 July 2024 - 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireImmutep Quarterly Activities Report Q3 FY24
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease control rateSubsequent to quarter end announced a positive preliminary response rate of 26.9% in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expressionPreclinical stu
- GlobeNewswire
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the studyData collection, cleaning, and analysis continues and additional data from TACTI-003 (Cohorts A & B), including complete response rate, will be released in H1 CY2024 SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP
- GlobeNewswire
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761’s pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ
